BridgeBio to Present Outcomes Data Through 42 Months from the Open-Label Extension of ATTRibute-CM, the Phase 3 Study of Acoramidis for Treatment of ATTR-CM, at 2024 AHA Scientific Sessions
BridgeBio Pharma (Nasdaq: BBIO) announced that outcomes data through 42 months from the open-label extension of ATTRibute-CM, its Phase 3 study of acoramidis in ATTR-CM, will be presented at the 2024 AHA Scientific Sessions. The featured science oral presentation, titled 'Acoramidis Reduces All-Cause Mortality (ACM) and Cardiovascular-Related Hospitalization (CVH): Initial Outcomes from the ATTRibute-CM Open-Label Extension (OLE) Study', will be delivered by Dr. Daniel Judge on November 18.
Additionally, BridgeBio will present three moderated digital posters on ATTR-CM, covering topics such as healthcare costs, baseline risk evolution, and acoramidis' impact on survival. These presentations will take place on November 17. The presentation and posters will be available on BridgeBio's website after the sessions.
BridgeBio Pharma (Nasdaq: BBIO) ha annunciato che i dati sui risultati fino a 42 mesi dall'estensione in aperto dello studio ATTRibute-CM, il suo studio di Fase 3 su acoramidis per l'ATTR-CM, saranno presentati nelle Sessioni Scientifiche AHA 2024. La presentazione scientifica principale, intitolata 'Acoramidis Riduce la Mortalità per Tutte le Cause (ACM) e il Ricovero Ospedaliero per Cause Cardiovascolari (CVH): Risultati Iniziali dallo Studio di Estensione in Aperto (OLE) di ATTRibute-CM', sarà tenuta dal Dr. Daniel Judge il 18 novembre.
Inoltre, BridgeBio presenterà tre poster digitali moderati su ATTR-CM, che tratteranno temi come i costi sanitari, l'evoluzione del rischio di base e l'impatto di acoramidis sulla sopravvivenza. Queste presentazioni si svolgeranno il 17 novembre. La presentazione e i poster saranno disponibili sul sito web di BridgeBio dopo le sessioni.
BridgeBio Pharma (Nasdaq: BBIO) anunció que los datos de resultados hasta 42 meses de la extensión a etiqueta abierta del estudio ATTRibute-CM, su estudio de Fase 3 de acoramidis en ATTR-CM, se presentarán en las Sesiones Científicas AHA 2024. La presentación oral destacada, titulada 'Acoramidis Reduce la Mortalidad por Todas las Causas (ACM) y las Hospitalizaciones Relacionadas con Enfermedades Cardiovasculares (CVH): Resultados Iniciales del Estudio de Extensión a Etiqueta Abierta (OLE) de ATTRibute-CM', será entregada por el Dr. Daniel Judge el 18 de noviembre.
Además, BridgeBio presentará tres carteles digitales moderados sobre ATTR-CM, abarcando temas como los costos de atención médica, la evolución del riesgo base y el impacto de acoramidis en la supervivencia. Estas presentaciones tendrán lugar el 17 de noviembre. La presentación y los carteles estarán disponibles en el sitio web de BridgeBio después de las sesiones.
BridgeBio Pharma (Nasdaq: BBIO)는 ATTR-CM에 대한 acoramidis의 3상 연구인 ATTRibute-CM의 오픈 라벨 연장 기간 동안 42개월의 결과 데이터가 2024 AHA 과학 세션에서 발표될 것이라고 발표했습니다. 제목이 'Acoramidis는 모든 원인으로 인한 사망률(ACM)과 심혈관 관련 입원(CVH)을 줄인다: ATTRibute-CM 오픈 라벨 연장(OLE) 연구의 초기 결과'인 주요 과학 발표는 다니엘 저지 박사가 11월 18일에 진행할 것입니다.
추가로, BridgeBio는 ATTR-CM에 대한 3개의 조정된 디지털 포스터를 발표하며, 의료 비용, 기초 위험의 변화 및 acoramidis의 생존에 대한 영향과 같은 주제를 다룰 것입니다. 이러한 발표는 11월 17일에 이루어질 것입니다. 발표 및 포스터는 세션 이후 BridgeBio 웹사이트에서 확인할 수 있습니다.
BridgeBio Pharma (Nasdaq: BBIO) a annoncé que les données de résultats sur 42 mois de l'extension en ouvert de l'étude ATTRibute-CM, son étude de Phase 3 sur acoramidis pour l'ATTR-CM, seront présentées lors des Sessions Scientifiques AHA 2024. La présentation orale scientifique phare, intitulée 'Acoramidis Réduit la Mortalité Toutes Causes Confondues (ACM) et l'Hospitalisation Liée aux Maladies Cardiovasculaires (CVH) : Résultats Initiaux de l'Étude d'Extension en Ouvert (OLE) d'ATTRibute-CM', sera faite par Dr. Daniel Judge le 18 novembre.
De plus, BridgeBio présentera trois posters numériques modérés sur l'ATTR-CM, couvrant des sujets tels que les coûts de soins de santé, l'évolution du risque de base et l'impact de l'acoramidis sur la survie. Ces présentations auront lieu le 17 novembre. La présentation et les posters seront disponibles sur le site Web de BridgeBio après les sessions.
BridgeBio Pharma (Nasdaq: BBIO) hat angekündigt, dass Daten zu den Ergebnissen über 42 Monate aus der offenen Erweiterung der ATTRibute-CM-Studie, seiner Phase-3-Studie zu acoramidis bei ATTR-CM, auf den wissenschaftlichen Sitzungen der AHA 2024 präsentiert werden. Der Hauptvortrag mit dem Titel 'Acoramidis reduziert die Gesamtsterblichkeit (ACM) und die Hospitalisierung aufgrund kardiovaskulärer Erkrankungen (CVH): Erste Ergebnisse der offenen Erweiterungsstudie (OLE) ATTRibute-CM' wird am 18. November von Dr. Daniel Judge gehalten.
Zusätzlich wird BridgeBio drei moderierte digitale Poster zu ATTR-CM präsentieren, die Themen wie Gesundheitskosten, die Entwicklung des Basisrisikos und die Auswirkungen von acoramidis auf die Überlebensdauer behandeln. Diese Präsentationen finden am 17. November statt. Die Präsentation und die Poster werden nach den Sitzungen auf der Website von BridgeBio verfügbar sein.
- Acoramidis reduces all-cause mortality and cardiovascular-related hospitalization in ATTR-CM patients
- BridgeBio's research selected for featured science oral presentation at AHA Scientific Sessions
- Long-term data (42 months) from Phase 3 study to be presented
- Multiple aspects of ATTR-CM research accepted for presentation, indicating strong scientific interest
- None.
Insights
The upcoming presentation of 42-month outcomes data from the ATTRibute-CM open-label extension study is a significant development for BridgeBio and the ATTR-CM treatment landscape. This long-term data will provide important insights into the efficacy and safety profile of acoramidis, potentially strengthening its position as a treatment option for ATTR-CM.
Key points to consider:
- The featured science oral presentation focusing on all-cause mortality and cardiovascular-related hospitalization reduction could significantly impact the drug's perceived value.
- Additional posters on healthcare costs, evolving baseline risks and survival improvements regardless of prior hospitalization will provide a comprehensive view of acoramidis' potential benefits.
- If positive, this data could support broader adoption of acoramidis and potentially influence treatment guidelines for ATTR-CM.
- Investors should watch for comparisons to existing treatments and any indications of improved long-term outcomes, which could drive market share and revenue growth for BridgeBio.
While the actual data is yet to be presented, the selection for a featured oral presentation suggests the results may be noteworthy. This could be a catalyst for BBIO's stock price, especially if the data exceeds market expectations.
PALO ALTO, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases, announced today that outcomes data through 42 months from the ongoing long-term open-label extension of ATTRibute-CM, its Phase 3 study of acoramidis in ATTR-CM, will be shared in a featured science oral presentation at the American Heart Association (AHA) Scientific Sessions, taking place in Chicago, Illinois on November 16 – 18, 2024. In addition to the presentation, BridgeBio was selected to share three posters in moderated poster sessions on ATTR-CM.
Featured Science Oral Presentation:
Acoramidis Reduces All-Cause Mortality (ACM) and Cardiovascular-Related Hospitalization (CVH): Initial Outcomes from the ATTRibute-CM Open-Label Extension (OLE) Study
Session Title: Featured Science: Amyloid, Hypertrophic, and Danon Cardiomyopathies: Targeted Therapies and Specific Populations
Presenter: Daniel Judge, M.D. of Medical University of South Carolina
Date: Monday, November 18 at 9:45 am CT/10:45 am ET
Moderated Digital Posters:
Costs and Healthcare Resource Utilization in Transthyretin Amyloid Cardiomyopathy Exceeds That of Generalized Heart Failure
Session Title: Socioeconomic Insights and Innovations in Heart Failure
Presenter: Justin Grodin, M.D. of UT Southwestern Medical Center
Date: Sunday, November 17 at 10:00 am CT/11:00 am ET
Evolving Baseline Risk in Patients with Transthyretin Amyloid Cardiomyopathy: A Systematic Literature Review of Clinical Trials
Session Title: Cardiac Amyloidosis 2024: Advances in Prognostication and Management
Presenter: Ahmad Masri, M.D. of Oregon Health & Science University
Date: Sunday, November 17 at 11:10 am CT/12:10 pm ET
Acoramidis Improved Survival in Patients with Transthyretin Cardiac Amyloidosis Regardless of Prior Cardiovascular Hospitalization
Session Title: Cardiac Amyloidosis 2024: Advances in Prognostication and Management
Presenter: Kevin Alexander, M.D. of Stanford University School of Medicine
Date: Sunday, November 17 at 11:20 am CT/12:20 pm ET
The presentation and posters will be available following the sessions on the Presentations page within the Investors section of the BridgeBio website at https://investor.bridgebio.com.
About BridgeBio Pharma, Inc.
BridgeBio Pharma (BridgeBio) is a commercial-stage biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015, and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn, Twitter and Facebook.
BridgeBio Contact:
Vikram Bali
contact@bridgebio.com
(650)-789-8220
FAQ
What are the key findings from BridgeBio's ATTRibute-CM study on acoramidis for ATTR-CM (BBIO)?
When and where will BridgeBio (BBIO) present the ATTRibute-CM study results for acoramidis?
What additional ATTR-CM research is BridgeBio (BBIO) presenting at the 2024 AHA Scientific Sessions?
How can investors access BridgeBio's (BBIO) AHA Scientific Sessions presentations?
